Dexmedetomidine

Sedation management in intensive care units has long had the clinical pain point of respiratory depression risk, and the advent of dexmedetomidine has filled the therapeutic gap in this细分 segment. As a highly selective α₂-adrenergic receptor agonist, it acts on α₂ receptors in the central and peripheral nervous systems to exert dose-dependent sedative and analgesic effects without causing significant respiratory depression, while also having anxiolytic and sympathetic excitatory inhibitory effects. At present, in addition to being widely used for perioperative sedation of ICU patients and sedation during diagnostic and therapeutic procedures for non-intubated patients, it has also been gradually expanded to scenarios such as pediatric anesthesia adjuvant therapy, cancer pain control, and perioperative cerebral protection for elderly patients. Its applicable population covers adult and pediatric patients, and it is one of the core drugs in the field of clinical sedation.

The global dexmedetomidine market size exceeded USD 1.2 billion in 2023, with a compound annual growth rate of around 7%, among which the Chinese market accounts for more than 35% and is the fastest-growing regional market. The domestic market has now formed a pattern of full competition between the originator drug and generic drugs. Generic preparations from more than 30 enterprises have been approved for marketing, and this variety has been included in multiple rounds of national centralized drug procurement. The maximum price reduction of winning bids compared with the originator drug exceeds 90%, and clinical accessibility has been greatly improved. The overall market has gradually shifted from the originator drug monopoly to a mature development stage dominated by generic drugs.

The originator enterprise of dexmedetomidine is Orion Corporation (Orion Pharma, Finland), and the originator brand name is "Precedex" (多美康). Its core compound patent expired in the United States in 2020, and the Chinese compound patent expired in 2019. The mainstream formulation approved for the originator drug is injection, with specifications of 2ml:200μg and 1ml:100μg, which have been included in the Chinese *Catalogue of Chemical Reference Preparations* and the FDA Reference Preparation Catalogue. Up to now, more than 50 domestic enterprises have completed the registration of dexmedetomidine API with the CDE, while more than 40 enterprises have obtained marketing approval for dexmedetomidine for injection and dexmedetomidine injection. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the impurity research needs in the process of generic drug R&D and quality control of dexmedetomidine, CATO can provide a full set of impurity reference standards for this API. Most of the products are available from stock. Orders for in-stock products placed before 16:00 can be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can fully meet the full-process needs of pharmaceutical enterprises for R&D and declaration as well as daily quality testing.